MYUNGMOON Pharm co.,Ltd (KRX:017180)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,722.00
+17.00 (1.00%)
Last updated: Dec 5, 2025, 10:59 AM KST
-5.23%
Market Cap 58.70B
Revenue (ttm) 193.64B
Net Income (ttm) 1.46B
Shares Out 33.43M
EPS (ttm) 42.67
PE Ratio 41.15
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,176
Average Volume 73,200
Open 1,711.00
Previous Close 1,705.00
Day's Range 1,691.00 - 1,736.00
52-Week Range 1,412.00 - 2,255.00
Beta 0.49
RSI 55.19
Earnings Date Nov 14, 2025

About MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics,... [Read more]

Sector Healthcare
Founded 1983
Employees 291
Stock Exchange Korea Stock Exchange
Ticker Symbol 017180
Full Company Profile

Financial Performance

In 2024, MYUNGMOON Pharm co.,Ltd's revenue was 186.44 billion, an increase of 9.95% compared to the previous year's 169.57 billion. Losses were -3.03 billion, -32.94% less than in 2023.

Financial Statements

News

There is no news available yet.